1. Home
  2. BBCP vs CBIO Comparison

BBCP vs CBIO Comparison

Compare BBCP & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Concrete Pumping Holdings Inc.

BBCP

Concrete Pumping Holdings Inc.

SELL

Current Price

$9.08

Market Cap

529.1M

ML Signal

SELL

Logo Crescent Biopharma Inc.

CBIO

Crescent Biopharma Inc.

HOLD

Current Price

$12.02

Market Cap

553.9M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
BBCP
CBIO
Founded
1983
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Engineering & Construction
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
529.1M
553.9M
IPO Year
2017
2013

Fundamental Metrics

Financial Performance
Metric
BBCP
CBIO
Price
$9.08
$12.02
Analyst Decision
Buy
Strong Buy
Analyst Count
3
8
Target Price
$13.50
★ $31.50
AVG Volume (30 Days)
131.8K
★ 475.6K
Earning Date
09-03-2026
11-05-2026
Dividend Yield
★ 5.70%
N/A
EPS Growth
N/A
★ N/A
EPS
★ 0.07
N/A
Revenue
★ $392,867,000.00
$18,500.00
Revenue This Year
$9.73
N/A
Revenue Next Year
$5.12
$177.36
P/E Ratio
$130.29
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$5.56
$8.72
52 Week High
$12.19
$27.41

Technical Indicators

Market Signals
Indicator
BBCP
CBIO
Relative Strength Index (RSI) 40.34 30.38
Support Level $8.89 $10.36
Resistance Level $9.64 $13.41
Average True Range (ATR) 0.31 1.06
MACD -0.07 -0.13
Stochastic Oscillator 29.03 9.66

Price Performance

Historical Comparison
BBCP
CBIO

About BBCP Concrete Pumping Holdings Inc.

Concrete Pumping Holdings Inc is a provider of concrete pumping services and concrete waste management services in the fragmented United States and United Kingdom markets. Its large fleet of specialized pumping equipment and trained operators enables it to deliver concrete placement solutions. The company's operating segments include U.S. Concrete Pumping, U.K. Operations, and U.S. Concrete Waste Management Services, with the majority of revenue generated from the U.S. Concrete Pumping segment. Geographically, it operates in the United States and the United Kingdom, generating majority of its revenue from the United States.

About CBIO Crescent Biopharma Inc.

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

Share on Social Networks: